Trial Search Results

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

This phase I trial is to find out the best dose, possible benefits and/or side effects of magrolimab in combination with dinutuximab in treating patients with neuroblastoma that has come back (relapsed) or does not respond to treatment (refractory) or relapsed osteosarcoma. Magrolimab and dinutuximab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. The combination of magrolimab and dinutuximab may shrink or stabilize relapsed or refractory neuroblastoma or relapsed osteosarcoma. In addition, this trial may help researchers find out if it is safe to give magrolimab and dinutuximab after surgery to remove tumors from the lungs.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):


  • Biological: Dinutuximab
  • Biological: Magrolimab
  • Procedure: Resection


Phase 1


Inclusion Criteria:

   - Patients must have a history of histologically or cytologically confirmed NBL or

   - Patients must have:

      - Relapsed/refractory high-risk neuroblastoma (NBL) (defined as disease recurrence
      after completion of therapy, progressive disease on therapy, or refractory
      disease during induction therapy) or

      - Relapsed osteosarcoma (relapsed after frontline therapy and/or there must not be
      any potentially curative treatment options available at the time of enrollment)

   - Cohort B1: Confirmed neuroblastoma: measurable NBL/ganglioneuroblastoma (defined as
   those lesions that can be accurately measured in at least one dimension (longest
   diameter to be recorded) as >= 10 mm with cross sectional imaging (computed tomography
   [CT] scan or magnetic resonance imaging [MRI]), or >= 10 mm with calipers by clinical
   exam). Chest x-ray cannot be used to determine eligibility. Lesions must be iobenguane
   (MIBG) positive, positron emission tomography (PET) avid (if patient has a history
   MIBG negative disease) or biopsy proven NBL/ganglioneuroblastoma

   - Cohort B2: Evaluable NBL (iobenguane [MIBG] and/or bone marrow disease only)

   - Cohort B3: Measurable osteosarcoma (defined as those lesions that can be accurately
   measured in at least one dimension (longest diameter to be recorded) as >= 10 mm (>= 1
   cm) with cross sectional imaging (CT scan, MRI,or calipers by clinical exam). Chest
   x-ray cannot be used to determine eligibility

   - Cohort B4: Patients with relapsed resectable pulmonary osteosarcoma who are scheduled
   for a surgical resection

   - Note: Subjects will not have measurable disease due to recently resected pulmonary
   metastases. Investigational therapy must begin within three weeks of resection. Staged
   resections are permissible; investigational therapy will be administered in between
   resections. Patients should receive one cycle of investigational therapy in between
   resections but can receive additional cycles to accommodate the most appropriate
   surgical schedule as determined by the treating physicians. Every effort will be made
   to have at least half of this cohort (five of ten patients) be those requiring a
   staged resection

   - There is no limit to the number of prior treatment regimens. Patients must have fully
   recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or
   radiotherapy prior to initiation of study treatment. Acute toxicity of any previous
   therapy must have resolved to grade 1 or less or stabilized, unless specified

      - Myelosuppressive chemotherapy: Patients must not have received myelosuppressive
      chemotherapy within 3 weeks of initiation of study treatment (6 weeks if prior

      - Hematopoietic growth factors: At least 7 days must have elapsed since the
      completion of therapy with a growth factor. At least 14 days must have elapsed
      after receiving pegfilgrastim

      - At least 7 days must have elapsed since the completion of therapy with a biologic
      agent, targeted agent, tyrosine kinase inhibitor or a metronomic
      non-myelosuppressive regimen

      - At least 4 weeks must have elapsed since prior therapy with 131I-MIBG

      - Monoclonal antibodies: At least 3 weeks must have elapsed since prior therapy
      that included a monoclonal antibody

      - Patients who have received prior therapy with GD2 antibodies, regardless of
      response to therapy, will be eligible

      - At least 7 days must have elapsed since the last pharmacologic dose of systemic

   - Arm A: Age >= 1 or < 18 years of age

   - Arm B: Age >= 1 or =< 35 years of age

   - Eastern Cooperative Oncology Group (ECOG) performance status =< 2; Subjects > 16 years
   of age: Karnofsky >= 50%; Subjects =< 16 years of age: Lansky scale >= 50%

   - Absolute neutrophil count >= 1,000/mcL

   - Hemoglobin >= 9.5 g/dL, transfusion support acceptable

   - Platelets >= 100,000/mcL, independent of transfusions

   - Total bilirubin =< 1.5 X institutional upper limit of normal (ULN) for age (sum of
   conjugated and unconjugated)

   - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase
   [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
   =< 5 x institutional ULN

   - Creatinine =< institutional ULN OR glomerular filtration rate (GFR) >= 70 mL/min/1.73

   - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral
   therapy with undetectable viral load within 6 months are eligible for this trial

   - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral
   load must be undetectable on suppressive therapy, if indicated

   - Patients with a history of hepatitis C virus (HCV) infection must have been treated
   and cured. For patients with HCV infection who are currently on treatment, they are
   eligible if they have an undetectable HCV viral load

   - Patients with a prior or concurrent malignancy whose natural history or treatment does
   not have the potential to interfere with the safety or efficacy assessment of the
   investigational regimen are eligible for this trial

   - Patients with known history or current symptoms of cardiac disease, or history of
   treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac
   function using the New York Heart Association Functional Classification. To be
   eligible for this trial, patients should be class 2B or better

   - Female patients of childbearing potential must not be nursing or planning to be
   pregnant and must have a negative urine or serum pregnancy test within 30 days before
   enrollment and within 72 hours before the first administration of study treatment

      - Note: Females who have undergone surgical sterilization or who have been
      postmenopausal for at least 2 years are not considered to be of childbearing

   - The effects of Hu5F9-G4 (magrolimab) monoclonal antibody on the developing human fetus
   are unknown and dinutuximab is known to be teratogenic. For this reason, female
   patients of childbearing potential must be willing to use one highly effective method
   of contraception (hormonal or barrier method of birth control; abstinence) prior to
   study entry, during the study and continue for 4 months after the last dose of study
   treatment. Should a woman become pregnant or suspect she is pregnant while she or her
   partner is participating in this study, she should inform her treating physician

      - Male patients who are sexually active with a woman of childbearing potential
      (WOCBP) and who have not had vasectomies must be willing to use a barrier method
      of contraception (condom plus spermicidal gel) and refrain from sperm donation
      during the study and for 4 months after the last dose of study treatment. If the
      partner is pregnant, male patients must use barrier method contraception (condom)
      during the study and for 4 months after the last dose of study treatment to
      prevent fetal exposure to study treatment

   - All patients and/or their parents or legally authorized representatives must have the
   ability to understand and the willingness to sign a written informed consent. Assent,
   where appropriate, will be obtained according to local institutional policy

   - Cardiac ejection fraction >= 45% or shortening fraction >= 28%, no evidence of
   physiologically significant pericardial effusion as determined by an echocardiogram
   (ECHO), multigated acquisition scan (MUGA) or cardiac MRI. No clinically significant
   electrocardiogram (ECG) findings that in the judgment of the treating investigator
   would present a contraindication for treatment

Exclusion Criteria:

   - History of allergic reactions attributed to compounds of similar chemical or biologic
   composition to anti-GD2 monoclonal antibody (dinutuximab) or Hu5F9-G4 (magrolimab)
   monoclonal antibody or other agents used in this study

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements

   - Patients who are receiving any other investigational agents

   - Pregnant women are excluded from this study because Hu5F9-G4 (magrolimab) is a
   monoclonal antibody on the developing human fetus are unknown and dinutuximab may
   cause fetal harm. Because there is an unknown but potential risk for adverse events in
   nursing infants secondary to treatment of the mother with Hu5F9-G4 (magrolimab) or
   dinutuximab, breastfeeding should be discontinued if the mother is treated with
   Hu5F9-G4 (magrolimab) or dinutuximab

   - Patients who have received prior treatment with CD47 or SIRPalpha-targeting agents

   - Patients with red blood cell (RBC) transfusion dependence, defined as requiring more
   than 2 units of RBCs transfused during the 4-week period prior to screening. RBC
   transfusions are permitted during the screening period and prior to enrollment

   - Patients with known inherited or acquired bleeding disorders are not eligible

   - Patients with prior hemolytic anemia or Evans syndrome in the last 3 months

   - Patients with significant medical diseases that would worsen the risk-benefit ratio of
   participating in this study. This includes but is not limited to acute myocardial
   infarction within the last 6 months, unstable angina, significant acute or chronic
   infections, or severely immunocompromised state

   - Patients on the following medications at the time of study treatment initiation:

      - Immunotherapy or immunosuppressive drugs (e.g. chemotherapy or systemic
      corticosteroids) EXCEPT for the following:

         - The only exception is for patients known to require 2 mg/kg or less of
         hydrocortisone (or an equivalent dose of an alternative corticosteroid) as
         premedication for blood product administration in order to avoid allergic
         transfusion reactions. The use of conventional doses of inhaled steroids for
         the treatment of asthma is permitted, as is the use of physiologic doses of
         steroids for patients with known adrenal insufficiency

      - Growth factors (granulocyte colony stimulating factor or granulocyte macrophage
      colony stimulating factor) EXCEPT for erythropoietin and darbepoietin alpha

      - Herbal remedies with immunostimulating properties (e.g., mistletoe extract) or
      known to potentially interfere with major organ function (e.g. hypericin)

   - Patients administered a live vaccine within 28 days prior to initiation of study

   - Patients with untreated central nervous system (CNS) metastasis.

      - Patients with previous CNS tumor involvement that has been treated and is stable
      for at least 4 weeks following completion of therapy are permitted

      - Patients who are clinically stable as evidenced by no requirements for
      corticosteroids, no evolving neurologic deficits, and no progression of residual
      brain abnormalities without specific therapy, are permitted

      - Patients with asymptomatic subcentemeric CNS lesions are permitted if no
      immediate radiation or surgery is indicated

Ages Eligible for Study

1 Year - 35 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina (Tina) R Baggott